Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED  

Gold Index: 82941

You are here: home  > Pharmaceutical Chemicals API  > Psychotropic Drugs API  > mexidol CAS 127464-43-1 2-Ethyl-6-Methyl-3-pyridinol butanoate

mexidol CAS 127464-43-1 2-Ethyl-6-Methyl-3-pyridinol butanoate 

Payment Terms: T/T,L/C,WU 
Place of Origin: Sichuan, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C8H11NO.C4H6O4
Production Capacity: 200Ton/Year
Delivery Date: Within 7 days
CAS: 127464-43-1
Appearance: white powder
Molecular formula: C8H11NO.C4H6O4
Molecular weight: 255.268
Means of Transport: Ocean,Land,Air
Packing: According to the request of...
Brand: MOSINTER
Name: mexidol
Alias: 2-Ethyl-6-Methyl-3-pyridino...
Assay: 97%

emoxypine has a wide range of applications in medical practice. It purportedly exercises anxiolytic, anti-stress, anti-alcohol,anticonvulsant

mexidol (CAS: 127464-43-1)


Synonyms2-Ethyl-6-methyl-3-pyridinol butanoate (1:1); 2-ethyl-6-methylpyridin-3-ol butanedioate (1:1)
Molecular FormulaC12H17NO5
Molecular Weight255.2671
InChIInChI=1/C8H11NO.C4H6O4/c1-3-7-8(10)5-4-6(2)9-7;5-3(6)1-2-4(7)8/h4-5,10H,3H2,1-2H3;1-2H2,(H,5,6)(H,7,8)
CAS Registry Number127464-43-1
Molecular Structure
Boiling point280.6°C at 760 mmHg
Flash point123.5°C
Vapour Pressur0.0022mmHg at 25°C

History

Emoxypine was first synthesized by L.D. Smirnov and K.M. Dumayev, then studied and developed in the Institute of Pharmacology, Russian Academy of Medical Sciences and National Scientific Center of Bioactive Substances Safety.

Use

In Russia, emoxypine has a wide range of applications in medical practice. It purportedly exercises anxiolytic, anti-stress, anti-alcohol,anticonvulsant, nootropic, neuroprotective and anti-inflammatory action. Emoxypine presumably improves cerebral blood circulation, inhibits thrombocyte aggregation, lowers cholesterol levels, has cardioprotective and antiatherosclerotic action.

Mechanism of action

Emoxypine's mechanism of action is believed to be its antioxidant and membrane-protective effects with the following key components:

  • Emoxypine effectively inhibits free radical oxidation of biomembrane lipids, reacts to peroxide radicals of lipids primary and hydroxyl radical of peptides

  • Increases the activity of antioxidant enzymes, specifically that of superoxide dismutase, responsible for the formation and consumption of lipid peroxides and active oxygen forms

  • Inhibits free radicals during the synthesis of prostaglandin catalyzed cyclooxygenase and lipoxygenase, increases the correlation prostacyclin/thromboxane A2 and blocks the leukotriene formation

  • Increases the content of polar fraction of lipids (phosphatidyl serine and phosphatidyl inositol) and reduces the cholesterol/phospholipids ratio which proves its lipid-regulatory properties; shifts structure transition into the low temperature zones, that is provokes the reduction of membrane viscosity and the increase of its fluidity, increases lipid-protein ration.

  • Modulates the activity of membrane-bound enzymes: phosphodiesterase, cyclic nucleotides, adenylate cyclase, aldoreductase, acetylcholinesterase.

  • Modulates the receptor complexes of the brain membranes, i.e. benzodiazepine, GABA, acetylcholine receptors by increasing their binding ability.

  • Stabilizes biomembranes, i.e. membrane structures of blood cells - erythrocytes and thrombocytes during their haemolysis or mechanical injury accompanied by the formation of free radicals.

  • Changes the monoamine level and increases the dopamine content in the brain.


  • Clinical study

  • One study determined the effectiveness of emoxypine in 205 patients with clinical manifestations of lumbosacral radiculopathy (LSR). Patients were divided into two groups, and further were divided into subgroups depending on the presence of motor disturbances. All patients received a course of conventional medical treatment and physiotherapy; main group additionally received emoxypine. Thereafter, clinical-neurological control of long-term results of treatment in subgroups of patients was performed. The results showed that the use of emoxypine in the combined therapy of patients with LSR lead to significant and persistent reduction of severity of pain syndrome and rapid recovery of function of spinal roots and peripheral nerves compared with conventional therapy.



mexidol  CAS: 127464-43-1   2-Ethyl-6-Methyl-3-pyridinol butanoate

mexidol  CAS: 127464-43-1   2-Ethyl-6-Methyl-3-pyridinol butanoate

bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: